Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity - Wikidata - wikimedia - TriplyDB

Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity

Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity

http://www.wikidata.org/entity/Q24648175

about

Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Honokiol: a novel natural agent for cancer prevention and therapy 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects.Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells.Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways.Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).Honokiol targets mitochondria to halt cancer progression and metastasis.Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway.The prospective role of plant products in radiotherapy of cancer: a current overview.Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report.

P2860

Q21560841-9AAE969D-01ED-4B27-8FA4-78E9CEF475DC Q26778234-4D4E0DCD-14CD-4695-A054-EC084AA1C26E Q27027050-717F01CB-1A87-4FFF-A341-F87A914621B1 Q30414471-6DF5F86E-77FF-4301-B1EE-01E50C3932FD Q30456053-2F04C804-0EE6-4D1A-A7DB-512181C623D4 Q35562099-33B07586-4039-4A5D-83BD-901EC729165D Q35884092-A581337B-1BD8-4AC4-9485-049AEBB6FDEF Q35916392-C6C189F8-B5C9-4CC9-9C38-478E4A703E22 Q37042612-88074326-4239-4404-9B82-118A79F0DC1A Q37702382-18A7449F-4726-41CD-9B59-5104F6C7213A Q38104756-BAA0D923-3CE0-4F95-807B-4F8BD8D9B127 Q38714359-78716EF9-9227-4FA2-ABD5-6A03198E1EE9 Q38858961-42EAC06F-6D93-4C0A-891D-5A4161F520AC Q39227892-F2D60891-C3C0-4D3C-B6A1-2DFE633ACD5D Q39298087-1BE7663B-7243-49CC-83C0-6A65625C23BA Q40239123-A9C8769C-B1D9-4447-A406-51A755FFD56F Q42656470-2C4E8E9B-AA0F-48EE-B7AC-1E849EDA6176 Q42717046-33311EDB-FFAA-4CB3-B611-7CE9AB8D8AED

P2860

Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity

http://www.wikidata.org/entity/Q24648175

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@ast

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@en

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@nl

type

label

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@ast

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@en

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@nl

prefLabel

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@ast

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@en

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@nl

P1433

Q24648175-457D12B9-76CC-4B3F-B0B2-A80DCF473FAB

P1476

Q24648175-2C7A2621-F969-41C9-A73E-48AAB04911BE

P2093

Q24648175-103E93E7-39FF-4495-9F3F-5E196F0129BC

Q24648175-1B95722E-65A8-4999-B593-F94410B379ED

Q24648175-1FCF2079-D4C2-495F-B80A-A53CE91F275A

Q24648175-391FC81C-7CA6-418D-AB19-1CB1CD56EE3C

Q24648175-3F58F89F-F87B-4EDF-8949-B4A15551DA91

Q24648175-465861D6-4413-469C-9048-950A399FC9CA

Q24648175-6DD98FE3-E586-41F6-9C66-E620F89A63A0

Q24648175-7C974345-E028-4678-80DA-C10DD1707452

Q24648175-A34DB476-81C1-4CA1-9F34-14CABB50E9D1

Q24648175-BC5BE092-D801-4A15-A1EB-CADA606FA1BD

P2860

Q24648175-141FF041-3D42-4640-804A-E5057F0DDF24

Q24648175-2B59A486-8C68-4EF0-9359-A686F662EB4D

Q24648175-4B2C236B-E3BF-4E78-ACA1-35618E8F6AD7

Q24648175-4CBAF76B-A592-433D-9FCA-F2955486579A

Q24648175-5197DD23-31EC-4C2D-8A54-8629B5B99911

Q24648175-5352B3CC-1E28-4BB3-B4CF-E12AF02E4F0A

Q24648175-645471E1-D683-4BFD-A661-F8841F5AE048

Q24648175-704D19F0-02CC-451D-B1B2-2110CC68E674

Q24648175-714119C6-CEB7-4263-98D0-D744CC92D6FA

Q24648175-73D1E4BE-FA81-4453-A128-F52A5530AE76

P2888

Q24648175-04345F6F-7C0C-4470-9DD8-3E5C902FD751

P304

Q24648175-D2C18530-2329-4E4F-A214-ACBDA2C9DAD6

P31

Q24648175-049486C6-30DF-4A56-8BBC-05C050DA6829

P3181

Q24648175-9BDC049A-44FB-4A5D-9454-5C147831F5CC

P356

Q24648175-8255ACAB-E1B9-4226-B263-87D007BF7EB7

P407

Q24648175-F4638209-5DBF-412E-934E-4F5FF0F9F18D

P433

Q24648175-71D2D7F7-2C83-4C17-AE6C-7F3C80003C65

P478

Q24648175-728CB423-78D9-4BDB-8EB4-7546517C18DD

P577

Q24648175-83BEDDDA-424F-4A08-81ED-E6EB7A9B3057

P5875

Q24648175-E51B19FB-A421-44DF-A268-4E9E8E652AD0

P6179

Q24648175-C15A6B59-5F54-4C53-9793-B1E35DB8A1CC

P698

Q24648175-55638A66-EF55-4435-A258-87D8330AC41F

P921

Q24648175-0AAECE7A-AAA4-47BE-86C2-25730335C868

P932

Q24648175-D416CFF0-7AAA-4FFE-95A1-210925375D16

P3181

P356

EMM.2008.40.6.617

P1433

Experimental and Molecular Medicine

P1476

Liposomal honokiol, a potent a ...... cy without increasing toxicity

@en

P2093

Fan Zhang

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Jia Hu

http://www.w3.org/2001/XMLSchema#string

Li Juan Chen

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Ming Hai Tang

http://www.w3.org/2001/XMLSchema#string

Ping Li Chen

http://www.w3.org/2001/XMLSchema#string

Wen Li Hou

http://www.w3.org/2001/XMLSchema#string

Xia Zhao

http://www.w3.org/2001/XMLSchema#string

Xian Huo Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

Development of investigational radiation modifiers.

Honokiol: a potent chemotherapy candidate for human colorectal carcinoma

Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO.

Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice.

Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines.

P2888

emm.2008.40.6.617

P304

617-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1424166

http://www.w3.org/2001/XMLSchema#string

P356

10.3858/EMM.2008.40.6.617

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23713650

http://www.w3.org/2001/XMLSchema#string

P6179

1039901005

http://www.w3.org/2001/XMLSchema#string

P698

19116447

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

2679338

http://www.w3.org/2001/XMLSchema#string